除了胜利，我们别无选择。
We have no other option except victory.
China’s First Inhaled Covid-19 Vaccine Is Applying for Emergency Use, Top Epidemiologist Says.
June 4 -- China's first inhalation-based Covid-19 vaccine, which does not need needles or low storage temperatures, is applying for emergency use in the country, top epidemiologist Chen Wei, 陈伟 said at the Pujiang Innovation Forum yesterday.
The Convidecia nasal spray vaccine, developed by vaccine maker CanSino Biologics and Chen’s home institution of the Institute of Bioengineering at the Academy of Military Medical Sciences, uses the same formula as Tianjin-based CanSino’s recombinant coronavirus vaccine, and is atomized by a special device for nebulized inhalation, which is less painful than traditional intramuscular injections and more conducive to mass distribution.
It only needs one-fifth of a regular dose to stimulate immunity, is needle-free and does not need to be stored in special bottles or at ultra-low temperatures, Chen said.
The inhalation-based vaccine has reached Phase II clinical trials, Yu Xuefeng, chairman and chief executive officer of Tianjin-based CanSino, said on June 2.
The Chinese Academy of Engineering has also developed a separate vaccine that is effective against the Covid-19 variant first discovered in South Africa and is now applying for permission to start clinical trials, Chen said. This enhanced vaccine should be able to prevent other variants as well.
6 月 4 日——中国首个吸入型 Covid-19 疫苗，不需要针头或低储存温度，正在申请该国紧急使用，顶级流行病学家陈伟昨天在浦江创新论坛上说。
6 Yuè 4 rì——zhōngguó shǒu gè xīrù xíng Covid-19 yìmiáo, bù xūyào zhēntóu huò dī chúcún wēndù, zhèngzài shēnqǐng gāi guó jǐnjí shǐyòng, dǐngjí liúxíng bìng xué jiā chén wěi zuótiān zài pǔjiāng chuàngxīn lùntán shàng shuō.
Convidecia鼻腔喷雾疫苗由疫苗制造商康希诺生物和陈家军事医学科学院生物工程研究所研制，采用与天津康希诺重组冠状病毒疫苗相同的配方，通过特殊装置雾化 雾化吸入，与传统肌肉注射相比疼痛更小，更有利于质量分布。
Convidecia bíqiāng pēnwù yìmiáo yóu yìmiáo zhìzào shāng kāngxī nuò shēngwù hé chén jiā jūnshì yīxué kēxuéyuàn shēngwù gōngchéng yánjiū suǒ yánzhì, cǎiyòng yǔ tiānjīn kāngxī nuò chóngzǔ guānzhuàng bìngdú yìmóngpāng, tōngguò tèshū zhuāngzhì wù huà wù huà xīrù, yǔ chuántǒng jīròu zhùshè xiāng bǐ téngtòng gèng xiǎo, gèng yǒu lìyú zhìliàng fēnbù.
陈说，它只需要常规剂量的五分之一即可刺激免疫力，无需针头，无需储存在特殊瓶子中或超低温下。
Chén shuō, tā zhǐ xūyào chángguī jìliàng de wǔ fēn zhī yī jí kě cìjī miǎnyì lì, wúxū zhēntóu, wúxū chúcún zài tèshū píngzi zhōng huò chāodīwēn xià.
总部位于天津的 CanSino 董事长兼首席执行官于雪峰 6 月 2 日表示，吸入型疫苗已进入 II 期临床试验。
Zǒngbù wèiyú tiānjīn de CanSino dǒngshì zhǎng jiān shǒuxí zhíxíng guān yú xuě fēng 6 yuè 2 rì biǎoshì, xīrù xíng yìmiáo yǐ jìnrù II qī línchuáng shìyàn.
陈说，中国工程院还开发了一种单独的疫苗，该疫苗可有效对抗首次在南非发现的 Covid-19 变体，目前正在申请开始临床试验的许可。 这种增强型疫苗也应该能够预防其他变异。
Chén shuō, zhōngguó gōngchéngyuàn hái kāifāle yī zhǒng dāndú de yìmiáo, gāi yìmiáo kě yǒuxiào duìkàng shǒucì zài nánfēi fāxiàn de Covid-19 biàn tǐ, mùqián zhèngzài shēnqǐng kāishǐ línchuáng shìyàn de xǔkě. Zhè zhǒng zēngqiáng xíng yìmiáo yě yīnggāi nénggòu yùfáng qítā biànyì.
No comments:
Post a Comment